{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:21:05Z","timestamp":1767374465797,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.neuropharm.2020.108152","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T02:26:46Z","timestamp":1590719206000},"page":"108152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Carisoprodol pharmacokinetics and distribution in the nucleus accumbens correlates with behavioral effects in rats independent from its metabolism to meprobamate"],"prefix":"10.1016","volume":"174","author":[{"given":"Theresa M.","family":"Carbonaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vien","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Gatch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Prokai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108152_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/7854_2017_2","article-title":"Cross-species translational findings in the discriminative stimulus effects of ethanol","volume":"39","author":"Allen","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108152_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1309\/4KTM-CY6N-572P-7ERD","article-title":"Carisoprodol: an unrecognized drug of abuse","volume":"117","author":"Bailey","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.neuropharm.2020.108152_bib3","doi-asserted-by":"crossref","first-page":"9582","DOI":"10.1523\/JNEUROSCI.2366-09.2009","article-title":"Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens","volume":"29","author":"Besheer","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108152_bib4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.aap.2007.02.002","article-title":"The risk of traffic accidents after prescriptions of carisoprodol","volume":"29","author":"Bramness","year":"2007","journal-title":"Accid. Anal. Prev."},{"year":"2000","series-title":"NTP Technical Report on the Toxicity Studies of Carisoprodol (CAS No. 78-44-4) Administered by Gavage to F344\/N Rats and B6C3F1 Mice","author":"Chan","key":"10.1016\/j.neuropharm.2020.108152_bib5"},{"key":"10.1016\/j.neuropharm.2020.108152_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00008571-199610000-00002","article-title":"Formation of meprobamate from carisoprodol is catalysed by CYP2C19","volume":"6","author":"Dalen","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.neuropharm.2020.108152_bib7","first-page":"77330","article-title":"Schedules of Controlled Substances: Placement of Carisoprodol into Schedule IV","volume":"76","author":"Drug Enforcement Administration","year":"2011","journal-title":"Fed. Regist."},{"key":"10.1016\/j.neuropharm.2020.108152_bib8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.7326\/0003-4819-71-6-1209","article-title":"Codeine and its alternates for pain and cough relief","volume":"71","author":"Eddy","year":"1969","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neuropharm.2020.108152_bib9","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1345\/aph.1P339","article-title":"Carisoprodol legal status and patterns of abuse","volume":"44","author":"Fass","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2020.108152_bib10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1124\/dmd.107.015222","article-title":"In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids","volume":"35","author":"Frid\u00e9n","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2020.108152_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drugalcdep.2011.10.010","article-title":"Carisoprodol tolerance and precipitated withdrawal","volume":"12","author":"Gatch","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2020.108152_bib12","first-page":"180","article-title":"Abuse potential of Soma: the GABA(A) receptor as a target","volume":"1","author":"Gonzalez","year":"2009","journal-title":"Mol. Cell. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108152_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/jpet.109.151142","article-title":"Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies","volume":"329","author":"Gonzalez","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"year":"1979","series-title":"Substituent Constant for Correlation Analysis in Chemistry and Biology","author":"Hansch","key":"10.1016\/j.neuropharm.2020.108152_bib14"},{"key":"10.1016\/j.neuropharm.2020.108152_bib15","first-page":"1622","article-title":"Tolerance and dependence risk with the use of carisoprodol","volume":"69","author":"Heacock","year":"2004","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.neuropharm.2020.108152_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002130050694","article-title":"The discriminative stimulus effects of ethanol are mediated by NMDA and GABAA receptors in specific limbic brain regions","volume":"139","author":"Hodge","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108152_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0165-0173(99)00023-5","article-title":"The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking","volume":"31","author":"Ikemoto","year":"1999","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.neuropharm.2020.108152_bib18","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1111\/ejn.13374","article-title":"Modulation of sensitivity to alcohol by cortical and thalamic brain regions","volume":"44","author":"Jaramillo","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108152_bib19","series-title":"Drug Metabolism and Pharmacokinetics Quick Guide","first-page":"171","author":"Khojasteh","year":"2011"},{"key":"10.1016\/j.neuropharm.2020.108152_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bcp.2016.03.014","article-title":"GABA(A) receptor-mediated neurotransmission: not so simple after all","volume":"115","author":"Knoflach","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108152_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108152_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.neuropharm.2015.04.007","article-title":"Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors","volume":"97","author":"Kumar","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108152_bib23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/cr60274a001","article-title":"Partition coefficients and their uses","volume":"71","author":"Leo","year":"1971","journal-title":"Chem. Rev."},{"key":"10.1016\/j.neuropharm.2020.108152_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/00952999309002671","article-title":"Meprobamate dependence secondary to carisoprodol (Soma) use","volume":"19","author":"Littrell","year":"1993","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2020.108152_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1520\/JFS14738J","article-title":"Carisoprodol, meprobamate, and driving impairment","volume":"45","author":"Logan","year":"2000","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.neuropharm.2020.108152_bib26","doi-asserted-by":"crossref","first-page":"E531","DOI":"10.1097\/01.brs.0000146453.76528.7c","article-title":"Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States","volume":"29","author":"Luo","year":"2004","journal-title":"Spine"},{"key":"10.1016\/j.neuropharm.2020.108152_bib27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3109\/00952997809007027","article-title":"Carisoprodol dependence: a case report","volume":"5","author":"Morse","year":"1978","journal-title":"Am. J. Drug Alcohol Abuse"},{"year":"2011","series-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council","key":"10.1016\/j.neuropharm.2020.108152_bib28"},{"key":"10.1016\/j.neuropharm.2020.108152_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.genhosppsych.2012.07.011","article-title":"Carisoprodol: an underrecognized drug of abuse in north India","volume":"35","author":"Nebhinani","year":"2013","journal-title":"Gen. Hosp. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108152_bib30","first-page":"679","article-title":"Carisoprodol withdrawal induced delirium: a case study","volume":"3","author":"Ni","year":"2007","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2020.108152_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00007691-199408000-00001","article-title":"Carisoprodol elimination in humans. Ther","volume":"16","author":"Olsen","year":"1994","journal-title":"Drug Monit"},{"key":"10.1016\/j.neuropharm.2020.108152_bib32","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/BF02972986","article-title":"Effect of cimetidine and phenobarbital on metabolite kinetics of omeprazole in rats","volume":"28","author":"Park","year":"2005","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.neuropharm.2020.108152_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"year":"1986","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","key":"10.1016\/j.neuropharm.2020.108152_bib34"},{"key":"10.1016\/j.neuropharm.2020.108152_bib35","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/jms.3799","article-title":"Mass spectrometric analysis of carisoprodol and meprobamate in rat brain microdialysates","volume":"51","author":"Prokai","year":"2016","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.neuropharm.2020.108152_bib36","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1021\/jm020531t","article-title":"Centrally acting and metabolically stable thyrotropin-releasing hormone analogues by replacement of histidine with substituted pyridinium","volume":"47","author":"Prokai","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108152_bib37","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1592\/phco.24.17.1804.52333","article-title":"Carisoprodol withdrawal syndrome","volume":"24","author":"Reeves","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2020.108152_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/1874473711003010033","article-title":"Carisoprodol: abuse potential and withdrawal syndrome","volume":"3","author":"Reeves","year":"2010","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.neuropharm.2020.108152_bib39","first-page":"723","article-title":"Carisoprodol: a drug of continuing abuse","volume":"97","author":"Reeves","year":"1997","journal-title":"J. Am. Osteopath. Assoc."},{"key":"10.1016\/j.neuropharm.2020.108152_bib40","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0022-3565(24)36535-8","article-title":"Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate","volume":"280","author":"Rho","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"year":"2011","series-title":"Drug Abuse Warning Network, 2008","author":"Substance Abuse and Mental Health Services Administration","key":"10.1016\/j.neuropharm.2020.108152_bib41"},{"key":"10.1016\/j.neuropharm.2020.108152_bib42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jchromb.2003.08.036","article-title":"Assaying protein unbound drugs using microdialysis techniques","volume":"797","author":"Tsai","year":"2003","journal-title":"J. Chromatogr. B"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820302203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820302203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:04:13Z","timestamp":1758438253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820302203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":42,"alternative-id":["S0028390820302203"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108152","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carisoprodol pharmacokinetics and distribution in the nucleus accumbens correlates with behavioral effects in rats independent from its metabolism to meprobamate","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108152"}}